Compare ENTX & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | WIMI |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Israel | China |
| Employees | N/A | 86 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 18.9M |
| IPO Year | 2015 | 2019 |
| Metric | ENTX | WIMI |
|---|---|---|
| Price | $2.85 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 357.7K | 100.2K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ $1.24 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $1.07 |
| 52 Week High | $4.20 | $5.65 |
| Indicator | ENTX | WIMI |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 27.67 |
| Support Level | $2.73 | N/A |
| Resistance Level | $3.10 | $1.43 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 9.53 | 0.00 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.